VANGUARD GROUP INC 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 4:41 pm Sale | 2026-03-13 | 13G | BRIDGEBIO PHARMA INC BBIO | VANGUARD GROUP INC | 0 0.000% | -16,484,985 (Position Closed) | Filing |
| 2025-07-29 11:20 am Purchase | 2025-06-30 | 13G | BRIDGEBIO PHARMA INC BBIO | VANGUARD GROUP INC | 16,484,985 8.680% | 3,684,691 (+28.79%) | Filing |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | BRIDGEBIO PHARMA INC BBIO | VANGUARD GROUP INC | 12,800,294 7.360% | 2,208,839 (+20.85%) | Filing |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | BRIDGEBIO PHARMA INC BBIO | VANGUARD GROUP INC | 10,591,455 7.090% | 1,259,772 (+13.50%) | Filing |
| 2022-02-09 3:33 pm Purchase | 2021-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | VANGUARD GROUP INC | 9,331,683 6.340% | 2,890,371 (+44.87%) | Filing |